5.00Open5.00Pre Close0 Volume4 Open Interest17.50Strike Price0.00Turnover1130.22%IV-304.53%PremiumJan 17, 2025Expiry Date14.41Intrinsic Value100Multiplier12DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.4205Delta0.0613Gamma0.20Leverage Ratio-0.1035Theta-0.0039Rho-0.08Eff Leverage0.0022Vega
Revance Therapeutics Stock Discussion
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced an amended merger agreement where Crown will acquire all outstanding Revance shares for $3.10 per share in cash through a tender offer. The amendment comes after several developments, including Revance's settlement with Teoxane regarding distribution agreements and revised brand guidelines, which are expect...
📊⚡️📊
No comment yet